ClinicalTrials.gg

Diabetes Mellitus clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 8,294 studies for Diabetes Mellitus across more than 10 countries. 1,073 are recruiting or about to start. 3,463 of them are mainly about Diabetes Mellitus (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 14 narrower conditions too, such as Diabetes Mellitus, Type 2: 23,040 studies, 3,499 open.

ClinicalTrials.gov finds 24,654 studies for Diabetes Mellitus. How that becomes 8,292 here

This page counts the studies the registry files under Diabetes Mellitus, and those it files under no condition that list Diabetes Mellitusthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 24,654Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −14,539Filed under a narrower condition, counted on its own pageDiabetes Mellitus, Type 2 8,074 · Diabetes Mellitus, Type 1 2,626 · Diabetic Foot 786 · Diabetes, Gestational 693 · Prediabetic State 587 · Diabetic Retinopathy 502 · 8 more
  3. −159List Diabetes Mellitus as a condition, but the registry did not file them under itMost often written as “Type2 Diabetes Mellitus” (28), “Glucose Metabolism Disorders (Including Diabetes Mellitus)” (16), and “Type1 Diabetes Mellitus” (11). The registry filed them under other conditions only, most often Obesity (33) and Insulin Resistance (17).
  4. −1,664Match it another way232 name it in the title, 13 in a keyword, and 1,419 by a synonym or other text the search reads.
  5. 8,292The count on this page62 of them list Diabetes Mellitus in their own words; the registry filed them under no condition.

Status

Completed
5,413
Status unknown
882
Recruiting
650
Terminated
415
Not yet recruiting
328
Active, not recruiting
259

Phase

Phase 3
789
Phase 2
743
Phase 4
742
Phase 1
719
Early Phase 1
51

Where

United States
3,022
Germany
512
Canada
493
United Kingdom
463
China
417
France
352

Who develops what

Add Diabetes Mellitus to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 47 programs from 33 companies, 21 with this as their studies’ main aim; 8 with a live phase 3 study; 7 primary completions in the next 12 months. Compare Boryung Pharmaceutical, Eli Lilly and Jiangsu HengRui Medicine here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Insulin GlargineRecent, repeated
Evidence
  • NCT06767735 · Gan & Lee Pharmaceuticals · Phase 3 · live · comparator · “Insulin Glargine U100” · registered Jan 2025
  • NCT06370715 · Eli Lilly and Company · Phase 4 · background · “Insulin Glargine” · registered Apr 2024
  • NCT04974528 · Mannkind Corporation · Phase 3 · background · “Basal Insulin” · registered Jun 2021
  • NCT04022993 · Geropharm · Phase 3 · comparator · “Lantus Solostar, 100 Units/mL Subcutaneous Solution” · registered Jul 2019
  • NCT03371082 · Gan & Lee Pharmaceuticals · Phase 3 · comparator · “Lantus®” · registered Nov 2017
Sanofi65% of its industry studiesUS: Sanofi (FDA 2000) + 3 othersEU: Sanofi (EMA 2000) + 3 others22 studies
dapagliflozinRecent, repeated
Evidence
  • NCT05743907 · Dong-A ST Co., Ltd. · Phase 4 · comparator · “Forxiga” · registered Feb 2023
  • NCT05505994 · Daewoong Pharmaceutical Co. LTD. · Phase 3 · live · comparator · “Dapagliflozin” · registered Aug 2022
  • NCT04956263 · Youngene Therapeutics Inc., Ltd. · Phase 2 · comparator · “Dapagliflozin” · registered Jun 2021
AstraZeneca82% of its industry studiesUS: off-patent, 22 generics marketedEU: off-patent, 1 generic authorized22 studies
insulin degludecRecent, repeated
Evidence
  • NCT06767748 · Gan & Lee Pharmaceuticals · Phase 3 · live · comparator · “insulin degludec” · registered Jan 2025
  • NCT05463744 · Eli Lilly and Company · Phase 3 · comparator · “Insulin Degludec” · registered Jul 2022
  • NCT05362058 · Eli Lilly and Company · Phase 3 · comparator · “Insulin Degludec” · registered May 2022
Novo Nordisk A/S93% of its industry studiesUS: Novo Nordisk A/S (FDA 2015)EU: Novo Nordisk A/S (EMA 2013)23 studies

26 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
zenagamtide☆ Track1 live phase-3 study: NCT07533175Novo Nordisk A/S
GZR4☆ Track3 live phase-3 studies: NCT06767735, NCT06767761, NCT07165223Gan & Lee Pharmaceuticals
retatrutide☆ Track1 live phase-3 study: NCT06297603Eli Lilly and Company

The 3 in phase 3 with the nearest primary completion, of 47 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (7)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.DA-2811 · Dong-A ST Co., Ltd. · Phase 2 main aimNCT07239440 Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control — primary endpoint: HbA1c · 288 enrolled
  • Mar 2027 est.Insulin, Regular, Human, Basal insulin · Mannkind Corporation · Phase 2 named, not the main aimNCT07224321 INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes — primary endpoint: Percentage of participants with Continuous Glucose Meter (CGM) measured time in range (TIR) ≥70% · 100 enrolled
  • 7 Jul 2027 est.KAI-7535 · Kailera · Phase 2 registry mapping onlyNCT07497880 Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity — primary endpoint: Percent Change from Baseline in Body Weight at Week 44 for Participants Without Diabetes Mellitus · 306 enrolled

4 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Diabetes Mellitus studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here GLP-1 receptor agonists 20 open · SGLT2 inhibitors 19 open · DPP-4 inhibitors 4 open · Statins 3 open · Angiogenesis inhibitors 3 open

Coming up

363studies finish main data collection within a year10 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 650 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 195 (30%) stop at 75 or younger. 89 (14%) take children under 18. 30 (5%) are for women only and 9 (1%) for men only; 182 (28%) take healthy volunteers.

Recruiting studies that take each age, of 650
AgeWomenMen
1068 (10%)66 (10%)
18481 (74%)461 (71%)
30543 (84%)521 (80%)
40561 (86%)543 (84%)
50571 (88%)558 (86%)
65556 (86%)547 (84%)
75489 (75%)480 (74%)
85407 (63%)399 (61%)

Across all 8,294 studies, recruiting or not: 40% stop at 75 or younger and 24% at 65; 13% take children; 4% are for women only and 4% for men only; 25% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Diabetes Mellitus studies take

Of 247 phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 7 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 17 mo3–17 · 247 studies6 mo2–10 · 171 studies19 mo8–55 · 76 studies
Phase 1/234 mo21–60 · 40 studies——
Phase 227 mo12–51 · 147 studies14 mo8–28 · 65 studies45 mo21–100 · 82 studies
Phase 2/327 mo16–56 · 23 studies——
Phase 319 mo13–35 · 230 studies17 mo12–23 · 167 studies41 mo26–79 · 63 studies
Phase 424 mo13–40 · 197 studies16 mo10–22 · 48 studies29 mo15–53 · 149 studies
Interventional, no phase21 mo9–42 · 1,747 studies13 mo4–26 · 160 studies22 mo10–43 · 1,587 studies
Observational36 mo14–122 · 643 studies21 mo6–39 · 109 studies42 mo16–159 · 534 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Started recruiting17

Show 12 more

Newly registered27

Show 22 more

Studies

Recruiting first, then most recently updated. Showing 50 of 8,294. Browse all 8,294 → or search them.